This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cerner And ICON Team Up To Streamline Late Phase Research Studies

Stocks in this article: CERN

KANSAS CITY, Mo. and DUBLIN, Ireland, Jan. 8, 2013 (GLOBE NEWSWIRE) -- Cerner (Nasdaq:CERN), a global innovator in electronic health record (EHR) and research technology, and ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, have announced an agreement that will provide pharmaceutical and device sponsors with late phase research technology to streamline the collection of information related to the safety, effectiveness and value of their medical products.

As health care models continue to evolve, late phase research studies play a key role by providing additional assurance of product safety, comparative effectiveness, awareness of potential expanded indications for use and an understanding of the impact on patient outcomes and quality of life.

ICON selected Cerner's Discovere Late Phase solution as its system of choice for its late phase projects after an extensive evaluation process. " Discovere Late Phase is a highly scalable and flexible platform that is able to support late phase study management and provides sponsors with the ability to capture research data across multiple research sites," said Elizabeth Thiele, President of ICON's Late Phase & Outcomes Research division. "Cerner's Web-based research solution was built to accommodate the diversity of late phase studies, an improvement over other technologies that may have been retro-fitted from cumbersome legacy systems."

Discovere Late Phase reduces the time required to start late phase studies, provides sites with an easy-to-use system for compiling data and expedites the reporting of valuable data back to sponsors and regulators. The solution can also integrate into the EHR workflow giving site researchers the ability to electronically transcribe study-relevant data from the EHR directly into the online study forms. Additionally, the system supports the capture of participant surveys and patient-reported outcomes through its integrated electronic patient-reported outcomes (ePRO) capabilities.

"Combining ICON's expertise in study management with Cerner's late phase technology will greatly benefit study sponsors," said Mark Hoffman, PhD, Vice President of Cerner Research. "We look forward to ongoing collaboration with ICON focused on improving research and minimizing barriers to research participation."

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,337.98 +142.56 0.83%
S&P 500 0.00 -2.75 -0.14%
NASDAQ 4,619.3820 +53.2440 1.17%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs